Impact of neurologic signs and symptoms on functional status in peripheral neuropathies

Neurology

Volumn 52, Issue 1, 1999, Pages 151-156

  Molenaar, D S M ^a   Vermeulen, M ^b   De Visser, M ^b   De Haan, R ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; CORRELATION FUNCTION; DISEASE ASSOCIATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RATING SCALE;

EID: 0032928093     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.1.151     Document Type: Article

References (27)

1. Molenaar DSM, de Haan R, Vermeulen M. Impairment, disability or handicap in peripheral neuropathy: analysis of the use of outcome measures in clinical trials in patients with peripheral neuropathies. J Neurol Neurosurg Psychiatry 1995;59:165-169.
2. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36: 838-845.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122:561-568.
4. de Haan R, Limburg M. The relationship between impairment and functional health scales in the outcome of stroke. Cerebrovasc Dis 1994;4:19-23.
5. McGuire D, Garrison L, Armon C, ALS Study Group. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the sickness impact profile (SIP) in measuring progression of ALS. Neurology 1996;46:1442-1444.
6. Dyck PJ. Quantitating severity of neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. Peripheral neuropathy. 3rd ed. Philadelphia: WB Saunders, 1993:686-697.
7. Dyck PJ, Kratz KM, Lehman KA, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991;41:799-807.
8. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42:1164-1170.
9. Hoogendijk JE, de Visser M, Bolhuis PA, Hart AAM, Ongerboer de Visser BW. Hereditary motor and sensory neuropathy type I: clinical and neurographical features of the 17p duplication subtype. Muscle Nerve 1994;17:85-90.
10. Tack CJJ, Netten PM, Scheepers MH, Meyer JWG, Smits P, Lutterman J. Comparison of clinical examination, current and vibratory perception threshold in diabetic polyneuropathy. Neth J Med 1994;44:41-49.
11. Hahn AF, Boulton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Brain 1996;119:1067-1077.
12. Medical Research Council. Aids to the examination of the peripheral nerve injuries. London: Her Majesty's Stationery Office, 1981:1.
13. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103-1109.
14. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
15. Jacobs HM, Lutik A, Touw-Otten FWMM, de Melker RA. The sickness impact profile; results of a validation study of the Dutch version. Ned Tijdschr Geneeskd 1990;134:1950-1954.
16. de Haan R, Aaronson N, Limburg M, Hewer RL, van Crevel H. Measuring quality of life in stroke. Stroke 1993;24:320-327.
17. Read JL, Quinn RJ, Hoefer MA. Measuring overall health: an evaluation of three important approaches. J Chron Dis 1987; 40(suppl):17S-21S.
18. Rankin J Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957;2:200-215.
19. de Haan R, Horn J, Limburg M, Van Der Meulen J, Bossuyt P. A comparison of five stroke scales with measures of disability handicap, and quality of life. Stroke 1993;24:1178-1181.
20. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
21. Wolfe CD, Taub NA, Woodrow EJ, Burney PG. Assessment of scales of disability and handicap for stroke patients. Stroke 1991;22:1242-1244.
22. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
23. Notermans NC, Wokke JHJ, Franssen H, et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry 1993;56:1066-1071.
24. van Doom PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990;40:209-212.
25. Goodkin DE. Interferon beta-1b. Lancet 1994;344:1057-1060, 1702-1703.
26. Katz K, Tauenberger JK, Canella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34:661-669.
27. Hughes RA, Heywood P, Sharrack B. Drug trials in neuropathy. Baillieres Clin Neurol 1995;4:607-627.